Analyst
Lyric Partners
Equibles does not estimate personal net worth.
Joe Schwartz is recorded as Analyst at Lyric Partners. Joe Schwartz has spoken on 3 earnings calls and 1 other investor event across 4 companies, most recently for uniQure N.V. on November 4, 2026. Those appearances were for uniQure N.V. (QURE), Biomarin Pharmaceutical Inc (BMRN), Gossamer Bio, Inc. (GOSS) and Design Therapeutics, Inc. (DSGN). The companies whose calls Joe Schwartz spoke on are classified in the Healthcare sector.
“Given the FDA expects the confirmatory study to be well underway and potentially fully enrolled at the time of accelerated approval, and screening starts by year-end, and the decision date is about four months later on May 1st, we were wondering how many patients do you expect to have randomized or dosed by then?”
“With only about 10 kids per arm in Phase 2, what growth advantage over Vox Oga would convince you that it's real? And how does the model you've used to power Phase 3 address the potential for growth velocity to plateau if it doesn't increase commensurate with the CGMP increases you've seen at some point over the curve?”
“I was just wondering how uniform are the clinical benefits that you've seen in the 1MIG per KIG cohort? Were all patients clear responders, or was the mean 6.4-point MFARs benefit driven by any outliers?”
Lyric Partners
Analyst
Transcript header (unverified)
QURE
Biotechnology · Healthcare
GOSS
Biotechnology · Healthcare
